These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Sacituzumab tirumotecan showed “promising efficacy” regardless of PD-L1 status, said study presenter Yongmei Yin, MD, PhD.

An expert discusses the evolving role of biomarker testing in first-line metastatic triple-negative breast cancer (mTNBC), ...

In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck ...